News
We send the latest information from SMC Laboratories.
Redefinition from NAFLD/NASH to MASLD/MASH
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL) and the Asociacion Latinoamericana para el Estudio del Higado (ALEH) have collaborated to present a statement on disease definitions, names and diagnostic methods for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Title: A multi-society…
STAM™ Mice Is The Best NASH model For Microbiome Therapeutics Study
We are pleased to introduce the development of drugs for non-alcoholic steatohepatitis (NASH) focusing on the gut microbiome and overview of studies using our STAM™ mice. Currently, the development of treatment and prevention methods for various diseases targeting the gut microbiome is progressing around the world. The relationship between NASH and the gut microbiome,…
World Hepatitis Day 2023 ~ One life, one liver ~
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help everyone around the globe have a deeper understanding of hepatitis, so please read on if you would like to learn more. In 2010, the World Health Organization (WHO) designated July 28th as…
SMC attend Digital partnering events 【Bio Asia-Taiwan 2023】!
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering™ in Bio Asia-Taiwan 2023 from July 26th to 30th. We would love to have the opportunity to meet with you virtually and introduce ourselves and our preclinical models, so please join us! If you would like to discuss specific…
【Publication Archive】 Study focusing on iron metabolism and mitophagy for the treatment of NASH and HCC published in EMBO Rep.
Please take a look at published study focusing on intracellular iron metabolism and mitophagy as therapeutic targets for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). Title: Iron loss triggers mitophagy through induction of mitochondrial ferritin ► Full text LINK [Hara Y et al., EMBO Rep. 2020] In this paper, it has been shown that…
Announcement of webinar 【Chronic kidney disease model ~Instructions on how to Tubular injury score】
Today, we are excited to invite you to join our Webinar that will be taking place on July 20th (JST) from 9:30 AM. In this webinar, we will focus on preclinical study for chronic kidney disease (CKD). In particular, we will introduce how to evaluate renal injury based on pathological findings, which is one…
Webinar Archive
I am writing you today to share with you about our Webinar. We occasionally organize webinars focusing on NASH and IPF, which are our primary areas of interest. We have previously conducted webinars on various topics, and the recordings are available in our webinar archive. ▶ Webinar archive [ Link ] The topics…
89bio Inc. and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s 89bio Inc. (CA/ISR)will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM mouse model Abstract Number: SAT-243 Format: Poster Presenting Author: Maya…
AprilBio Co., Ltd., and SMC’s presentation at EASL Congress 2023 in Vienna, Austria!
SMC announced that our client’s AprilBio Co., Ltd., (KOR) will present results of a study using STAM™ mice at poster presentation at EASL Congress 2023 in Vienna, Austria, June 21-24, 2023. Presentation details are as follows: Abstract Title: APB-R3, a novel long-acting IL-18 binding protein, inhibits IL-18 activity, and thereby ameliorates NASH progress with…
Our article was published in Nature Brand magazine (Biopharma Dealmakers)!
It's about the concept of metabolic-associated fatty liver disease (MAFLD) and how we work with it, which could have important implications for drug development in non-alcoholic fatty liver disease (NAFLD). As we know, the lack of appropriate mouse models of the disease for NAFLD is a barrier to drug development and is thought…